|Summary sheet: LSZ|
|Common names||LSZ, LA-SS-Az, Diazedine, Lambda|
|Substitutive name||Lysergic acid 2,4-dimethylazetidide|
|Routes of Administration|
In the 2000s, a team led by David E. Nichols at Purdue University set to develop a rigid analog of LSD with the diethylamide group constrained into an azetidine ring in order to map the binding site at the 5-HT2A receptor.
LSZ has little to no history of human usage prior to 2012 when it appeared on some research chemical markets in the UK. LSZ later gained international popularity through a small cluster of mail-order novel psychedelic shops that appeared in 2012.
There have also been several unconfirmed reports of LSZ being synthesized in illicit laboratories and distributed on blotter paper or in liquid solution under names such as "Diazedine" and "λ" (or "Lambda").
As with psychedelics in general, LSZ does not meet the criteria for an addictive substance by the scientific community. Nevertheless, unpredictable adverse reactions such as uncontrollable anxiety, paranoia, delusions and psychotic breaks can always still occur, particularly among those who are predisposed to psychiatric disorders. While these negative reactions or "bad trips" can often be attributed to factors like the user's inexperience or improper preparation of their set and setting, they are known to happen spontaneously among even the most experienced of users as well. This is why despite its low likelihood of displaying any significant toxicity, it is still highly advised to approach this very potent, unpredictable, long-lasting, hallucinogenic substance with the proper amount of precaution, and harm reduction practices if choosing to use it.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal issues
- 6 See also
- 7 External links
- 8 References
LSZ, or d-lysergic acid 2,4-dimethylazetidide, is a semi-synthethic alkaloid of the lysergamide famiy. It contains a core structure of lysergic acid with an amine functional group bound to RN of the chemical structure. This core polycyclic structure is an indole derivative, and has tryptamine and phenethylamine groups embedded within it.
The structure contains a bicyclic hexahydroindole fused to a bicyclic quinoline group (lysergic acid). At carbon 8 of the quinoline, an amide group is bound. Additionally, the substitutions of the terminal nitrogen atom of the amide group form a 2,4-dimethylazetidide group. LSZ is additionally substituted at carbon 6 with a methyl group.
There are three possible stereoisomers around the azetidine ring with the (S,S)-(+) isomer being the most active. It is slightly more potent than LSD itself in drug discrimination tests using trained rats.
LSZ likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from LSZ's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
|This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding it.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. These effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- Analysis enhancement
- Conceptual thinking
- Creativity enhancement
- Emotion enhancement
- Immersion enhancement
- Increased music appreciation
- Memory suppression
- Novelty enhancement
- Personal bias suppression
- Spirituality enhancement
- Thought acceleration
- Thought disorganization
- Thought loops
- Time distortion
- Unity and interconnectedness
Anecdotal reports which describe the effects of this compound within our experience index include:
Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational LSZ do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because LSZ is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried LSZ suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
LSZ is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of LSZ are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). LSZ presents cross-tolerance with all psychedelics, meaning that all psychedelics will have a reduced effect after the consumption of LSZ.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- United Kingdom: As of January 7th, 2015, LSZ is specifically named in the U.K. Misuse of Drugs Act as a Class A drug.
- Switzerland: LSZ was added to the list of controlled substances on the 1st of December 2015.
- Latvia: LSZ is illegal in Latvia. Although it isn't officially scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1th, 2015.
- Sweden: Following its sale as a designer drug, LSZ was made illegal in Sweden on 26 January 2016.
- Denmark: As of August 25th, 2015, LSZ is specifically named on the list of illegal substances in Denmark.
- Nichols, D.E., Frescas S., Marona-Lewicka D., and Kurrasch-Orbaugh D.M. (2002). Lysergamides of Isomeric 2,4-Dimethylazetidines Map the Binding Orientation of the Diethylamide Moiety in the Potent Hallucinogenic Agent N,N-Diethyllysergamide (LSD). Journal of Medicinal Chemistry 2002 45 (19), 4344-4349. DOI: 10.1021/jm020153s
- ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" | https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/318693/UpdateGenericDefinitionTryptamines.pdf
- The Drug Revolution That No One Can Stop | https://medium.com/matter/the-drug-revolution-that-no-one-can-stop-19f753fb15e0#.fupvbuawp
- Life Is a Cosmic Giggle on the Breath of the Universe | http://www.vice.com/en_ca/read/life-is-a-cosmic-giggle-803-v18n5?Contentpage=3
- Cole, Krystle (2005). Lysergic. Indianapolis: Dog Ear Publishing. ISBN 1-59858-007-8.
- Lüscher, C., & Ungless, M. A. (2006). The Mechanistic Classification of Addictive Drugs, 3(11). https://doi.org/10.1371/journal.pmed.0030437
- Strassman, R. J. (1984). Adverse Reactions to Psychedelic Drugs: A Review of the Literature. The Journal of Nervous and Mental Disease, 172(10), 577-595. PMID: 6384428
- Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD) (PubMed.gov / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/12213075
- ACMD (10 June 2014). "Update of the Generic Definition for Tryptamines" (PDF). UK Home Office. p. 12. Retrieved 10 June 2014.
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (2.4.punkts) | http://likumi.lv/doc.php?id=121086
- (in Swedish) Folkhälsomyndigheten. | https://www.folkhalsomyndigheten.se/nyheter-och-press/nyhetsarkiv/2016/januari/31-nya-substanser-klassas-som-narkotika-eller-halsofarlig-vara/